Icon posted $317 million in revenue last quarter, a 26% jump over the previous year, and the CRO more than doubled its net income.
Irish CRO Icon pulled down a monster fourth quarter, with revenue skyrocketing 24% to $300 million, and the company predicts an even brighter 2013, projecting annual revenue of up to $1.3 billion, good for a 12% jump.
Irish CRO Icon has agreed to trade $52 million for Cross Country Healthcare's clinical trials operation, looking to expand its contract staffing, functional service and pharmacovigilance offerings.
Icon is continuing to change up its business model, kicking off a new functional service provider offering through its DOCS subsidiary.
Icon clocked a 19% jump in revenue and $24.6 million gain in net revenue in the third quarter, and the CRO is planning to ditch the Irish Stock Exchange in favor of a Nasdaq listing.
South Korea has long been touting itself as a go-to destination for clinical trials, and Icon would seem to agree, partnering with the Korea National Enterprise for Clinical Trials.
With some insight from the Association of Clinical Research Organizations (ACRO) and CROs, such as Icon and Covance, we at FierceCRO set out to identify countries that offer the right mix of features for outsourcing and clinical work. But rather than focus on markets with well-established CRO operations, we looked for promising, upwardly mobile countries.
Icon has entered into a strategic partnership with University College Dublin, teaming up with its hometown school to develop drugs, fund a fellowship and help construct a new science center for the university.
Icon ($ICLR) is expanding its capacity in the U.K., plotting to set up a 40,000-square-foot translational medicine operation within the Manchester Royal Infirmary Campus' Citylabs.
An Outsourcing-Pharma report breaks down the 2011 salaries and bonuses of four chief executives.